SLC2A1 (Solute Carrier Family 2 Member 1) encodes GLUT1 (Glucose Transporter 1), the principal glucose transporter expressed at the blood-brain barrier (BBB) and in many neural cell types . GLUT1 is a facilitative glucose transporter belonging to the SLC2A family that provides the critical link between systemic glucose supply and cerebral energy metabolism. The protein is essential for brain function — it ensures that the highly energy-dependent neurons and glial cells receive a constant supply of glucose, the brain's primary fuel.
GLUT1 dysfunction is implicated in a spectrum of neurodegenerative conditions. In Alzheimer's disease, GLUT1 reduction at the BBB contributes to brain glucose hypometabolism, which is among the earliest detectable abnormalities in AD and precedes clinical symptoms by decades . In Parkinson's disease, GLUT1 expression in the substantia nigra is compromised, exacerbating the energy crisis that makes dopaminergic neurons particularly vulnerable . Germline mutations in SLC2A1 cause GLUT1 deficiency syndrome, a metabolic encephalopathy characterized by early-onset epilepsy, developmental delay, and movement disorders, providing a human model of the consequences of impaired cerebral glucose transport .
¶ Gene and Protein Structure
| Property |
Value |
| Gene Symbol |
SLC2A1 |
| Full Name |
Solute Carrier Family 2 Member 1 (Glucose Transporter 1) |
| Alternative Names |
GLUT1, SLC2A1 |
| Chromosomal Location |
1p34.2 |
| NCBI Gene ID |
6513 |
| OMIM ID |
138140 |
| Ensembl ID |
ENSG00000117394 |
| UniProt ID |
P11166 |
| Gene Size |
~42 kb |
| Exons |
10 |
| Protein Length |
492 amino acids |
| Molecular Weight |
~54 kDa |
GLUT1 is a polytopic membrane protein with 12 transmembrane helices arranged in a characteristic major facilitator superfamily (MFS) fold :
flowchart TD
A["GLUT1 Structure"] --> B["N-terminal<br/>Intracellular (10 aa)"]
A --> C["TM1"]
A --> D["ECL1"]
A --> E["TM2"]
A --> F["ICL1"]
A --> G["TM3"]
A --> H["ECL2"]
A --> I["TM4-TM11"]
A --> J["TM12"]
A --> K["C-terminal<br/>Intracellular (30 aa)"]
C --> L["Glucose channel pore"]
E --> L
G --> L
I --> L
J --> L
B --> M["Kinase regulation sites"]
K --> M
H --> N["Glycosylation<br/>N140, N206"]
N --> O["BBB targeting signal"]
Key structural features:
- 12 transmembrane domains: Form the glucose channel pore. The transmembrane helices are arranged in two bundles of six, creating an inward-facing and outward-facing conformation for alternating access transport
- Intracellular N- and C-termini: The short intracellular termini contain regulatory phosphorylation sites and interact with signaling molecules
- Extracellular loop 2 (ECL2): Contains N-linked glycosylation sites (Asn140, Asn206) that are critical for correct folding and BBB targeting
- Inward-facing vs outward-facing conformations: GLUT1 alternates between conformations to facilitate facilitative diffusion
The GLUT1 transporter operates by alternating-access mechanism:
- Outward-facing state: Glucose-binding site exposed to extracellular space
- Inward-facing state: Glucose-binding site exposed to cytoplasm
- Transition: Substrate-induced conformational change moves glucose across the membrane
Key residues for glucose transport:
- Q282, E380: Predicted to form the glucose-binding pocket
- R400: Important for substrate recognition
- H160: Contributes to proton coupling in some contexts
GLUT1 is the primary glucose transporter at the neurovascular unit :
flowchart LR
A["Blood<br/>glucose ~5mM"] -->|"GLUT1 at<br/>luminal membrane"| B["Brain capillary<br/>endothelial cell"]
B -->|"GLUT1 at<br/>abluminal membrane"| C["Perivascular space"]
C -->|"GLUT1 on<br/>astrocyte end-feet"| D["Astrocyte"]
D -->|"Neuronal<br/>glucose uptake"| E["Neurons<br/>(also GLUT3)"]
F["Astrocyte<br/>glycogen"] -.->|"breakdown"| C
E --> G["ATP production"]
G --> H["Neurotransmission"]
G --> I["Ion homeostasis"]
Luminal membrane (blood-facing):
- High-density GLUT1 expression on the apical/luminal surface of brain capillary endothelial cells
- Captures glucose from blood (concentration ~5 mM under fasting conditions)
- Provides high-capacity, insulin-independent glucose uptake
Abluminal membrane (brain-facing):
- GLUT1 on the basolateral surface releases glucose into the brain interstitium
- Rate matches neuronal demand under normal conditions
Astrocyte end-feet:
- GLUT1 on astrocyte processes surrounding capillaries
- Captures glucose for astrocyte metabolism and glycogen storage
- Supports metabolic coupling between astrocytes and neurons
GLUT1 is expressed beyond the BBB in multiple neural cell types:
| Cell Type |
GLUT1 Expression |
Role |
| Brain capillary endothelial cells |
Very high |
BBB glucose transport |
| Astrocytes |
High |
Metabolic support, glycogen synthesis |
| Oligodendrocytes |
Moderate |
Myelin energy metabolism |
| Neural stem cells |
Moderate |
Development, neurogenesis |
| Mature neurons |
Low (GLUT3 dominant) |
Backup glucose uptake |
| Microglia |
Low |
Inflammatory energy demands |
GLUT1-mediated glucose transport supports multiple neural functions:
- ATP production: Glycolysis and oxidative phosphorylation fueled by imported glucose
- Neurotransmitter synthesis: Glucose provides carbon for glutamate and GABA synthesis
- Ion homeostasis: ATP-dependent Na+/K+-ATPase maintains resting potential
- Action potentials: Activity-dependent glucose consumption during firing
- Glial metabolism: Supports astrocyte glycogen storage and lactate production
- Myelin maintenance: Oligodendrocyte glucose needs for lipid synthesis
GLUT1 expression and activity are tightly regulated:
Transcriptional regulation:
- Hypoxia-inducible factor (HIF-1α): Upregulates GLUT1 under low oxygen
- cAMP/PKA pathway: Modulates GLUT1 transcription
- Insulin-independent: Unlike GLUT4, GLUT1 is not acutely regulated by insulin
Post-translational regulation:
- N-linked glycosylation: Required for correct trafficking to membrane
- Kinase phosphorylation: PKA and AMPK can modulate activity
- Proteolytic cleavage: Alternative splicing can produce truncated forms
- Ubiquitination: Regulates protein stability
Cellular redistribution:
- GLUT1 functions as a constitutively active transporter at the BBB
- Unlike GLUT4, it does not undergo insulin-dependent translocation
- Its regulation is primarily at the level of expression and degradation
GLUT1 reduction is among the earliest and most consistent metabolic abnormalities in AD :
- BBB GLUT1 reduction: Post-mortem studies consistently show decreased GLUT1 in AD cortex and hippocampus
- Glucose hypometabolism: FDG-PET imaging reveals reduced cerebral glucose metabolism years before symptoms
- Aβ-mediated downregulation: Amyloid-beta directly reduces GLUT1 expression through multiple pathways
- Tau pathology interaction: GLUT1 reduction may accelerate tau phosphorylation through energy depletion
- Vascular contributions: GLUT1 reduction in the BBB contributes to neurovascular uncoupling
Mechanistic cascade:
flowchart TD
A["Aging + genetic risk"] --> B["GLUT1 expression decline at BBB"]
B --> C["Reduced cerebral glucose uptake"]
C --> D["ATP depletion in neurons"]
D --> E["Impaired neurotransmitter synthesis"]
D --> F["Na+/K+-ATPase dysfunction"]
F --> G["Neuronal hyperexcitability"]
C --> H["Compensatory GLUT3 upregulation (insufficient)"]
H --> I["Glucose supply-demand mismatch"]
A --> J["Aβ production/accumulation"]
J --> K["Aβ downregulates GLUT1"]
J --> L["Vascular dysfunction"]
K --> B
L --> M["BBB breakdown"]
M --> B
G --> N["Synaptic dysfunction"]
I --> N
N --> O["Cognitive decline"]
GLUT1 dysfunction contributes to the selective vulnerability of dopaminergic neurons in PD :
- Reduced GLUT1 in substantia nigra: GLUT1 expression is decreased in PD SN pars compacta neurons
- Energy crisis in dopaminergic neurons: These neurons have exceptionally high energy demands due to autonomous pacemaking
- Mitochondrial interaction: GLUT1 dysfunction compounds the effects of mitochondrial complex I deficiency in PD
- α-synuclein effects: α-synuclein pathology may impair glucose metabolism and GLUT1 function
- Levodopa response: Glucose metabolism in the striatum predicts therapeutic response
Heterozygous SLC2A1 mutations cause GLUT1 deficiency syndrome, a metabolic encephalopathy :
Clinical features:
- Early-onset epilepsy (often intractable)
- Developmental delay and intellectual disability
- Ataxia and movement disorders (paroxysmal ataxia, dystonia)
- Microcephaly
- Hemolytic anemia (in some variants)
Genotype-phenotype correlations:
- Loss-of-function mutations: More severe phenotypes
- Haploinsufficiency: Variable severity, often milder
- Dominant-negative effects: Some missense mutations act dominantly
Treatment:
- Ketogenic diet: Provides ketone bodies as alternative brain fuel
- Triheptanoin: Odd-chain fatty acid providing anaplerotic substrates
- Classic KD: High-fat, low-carbohydrate diet (75-80% fat)
- Modified Atkins: Less restrictive ketone-producing diet
GLUT1 dysfunction in ALS contributes to motor neuron energy failure :
- Motor neuron vulnerability: Motor neurons have high metabolic demands and rely on glucose transport
- GLUT1 in spinal cord: ALS spinal cord shows reduced GLUT1 in motor neurons and glia
- SOD1 models: GLUT1 reduction precedes motor neuron loss in SOD1-G93A mice
- Interaction with excitotoxicity: Energy depletion exacerbates glutamate-induced toxicity
GLUT1 reductions in FTD reflect metabolic contributions to non-AD dementia :
- Behavioral variant FTD: GLUT1 reduction in frontal cortex
- C9orf72-associated FTD: Metabolic dysfunction as part of disease mechanism
- Overlap with motor neuron disease: GLUT1 dysfunction in FTD-ALS spectrum
¶ Stroke and Cerebrovascular Disease
GLUT1 at the BBB is a critical determinant of stroke outcome :
- Ischemic vulnerability: Areas with high GLUT1-dependent glucose metabolism are most vulnerable
- Penumbra metabolism: GLUT1 expression in the ischemic penumbra determines salvageability
- Post-stroke recovery: GLUT1 upregulation in recovery phase supports neurogenesis
- Therapeutic targeting: Enhancing GLUT1 may improve post-stroke brain repair
GLUT1 reduction triggers a characteristic energy failure cascade:
- Glucose import reduction: Less glucose enters the brain
- ATP depletion: Glycolytic and oxidative phosphorylation are compromised
- Ion pump failure: Na+/K+-ATPase and Ca2+-ATPase cannot maintain gradients
- Membrane depolarization: Resting potential is disrupted
- Calcium dysregulation: Intracellular calcium rises
- Neurotransmitter imbalance: Synthesis is impaired, release is dysregulated
- Synaptic failure: Both excitatory and inhibitory transmission are compromised
- Neuronal death: If sustained, energy failure leads to cell death
GLUT1 dysfunction at the BBB disrupts the coupling between neural activity and blood flow:
- Baseline glucose supply: Reduced, limiting the ceiling of metabolic support
- Activity-dependent increase: Impaired capacity to increase delivery during demands
- fMRI signal: Contributes to the BOLD signal changes observed in neurodegenerative disease
- Functional impairment: Cognitive performance correlates with vascular metabolic support
GLUT1 reduction interfaces with all major neurodegeneration mechanisms:
- Aβ pathway: Aβ reduces GLUT1; reduced GLUT1 increases Aβ production
- Tau pathway: Energy failure activates GSK3-β, accelerating tau phosphorylation
- α-synuclein: Energy depletion sensitizes neurons to α-synuclein toxicity
- Mitochondrial dysfunction: Synergistic energy crisis compounds both defects
- Neuroinflammation: GLUT1 reduction in activated glia changes metabolic support
| Tissue |
GLUT1 Expression |
Primary Function |
| Brain (capillary endothelium) |
Very high |
BBB glucose transport |
| Brain (astrocytes) |
High |
Metabolic support |
| Erythrocytes |
Very high |
Glucose transport |
| Testis |
High |
Germ cell metabolism |
| Eye (retina) |
High |
Retinal glucose supply |
| Placenta |
High |
Fetal glucose supply |
| Liver |
Very low |
GLUT2 dominant |
| Muscle |
Low |
GLUT4 dominant |
- Cortex: High in all layers, particularly layer 4
- Hippocampus: High in CA1-CA3 and dentate gyrus
- Cerebellum: Moderate in Purkinje cells and granule cells
- Substantia nigra: Moderate to low in dopaminergic neurons
- White matter: GLUT1 in myelin-producing cells (oligodendrocytes)
- Spinal cord: Higher in ventral horn (motor neuron region)
- Fetal: GLUT1 expression appears early in brain capillary development
- Postnatal: Increases during brain development, peaks in adulthood
- Aging: GLUT1 expression gradually declines with age
- Disease: Additional decline in neurodegenerative conditions
Targeting GLUT1 for neurodegeneration therapy :
| Approach |
Mechanism |
Status |
| GLUT1 expression upregulation |
Increase transcription/translation |
Preclinical |
| Glycosylation enhancement |
Improve BBB targeting |
Early research |
| Small molecule activators |
Directly enhance transport activity |
Preclinical |
| Ketogenic diet |
Provide ketone bodies as alternative fuel |
Clinical in GLUT1DS |
| Ketone esters |
Alternative ketone delivery |
Phase II trials |
| Astrocyte metabolic support |
Improve pericyte and astrocyte function |
Preclinical |
GLUT1-related biomarkers for neurodegenerative disease:
- CSF glucose: Not reliable — systemic glucose dominates
- FDG-PET: Cerebral glucose metabolism as surrogate
- BBB permeability markers: Soluble GLUT1 fragments (research)
- Magnetic resonance spectroscopy: Brain glucose levels (experimental)
The ketogenic diet bypasses GLUT1-dependent glucose transport by providing ketone bodies:
Mechanisms of ketone body benefit:
- Ketone bodies enter the brain via MCT1 and MCT2 transporters (SLC16A1, SLC16A7)
- Ketone bodies are more efficient fuels than glucose per molecule of oxygen
- Ketone metabolism produces more ATP per molecule than glycolysis
- Ketone bodies are neuroprotective through multiple mechanisms
Clinical evidence:
- Effective in GLUT1 deficiency syndrome (direct treatment)
- Benefits in some epilepsy patients (metabolic seizure suppression)
- Emerging evidence in AD and PD (metabolic support)
- Cognitive benefits in aging and MCI populations
| Transporter |
Gene |
Cell Type |
Kinetic Properties |
| GLUT1 |
SLC2A1 |
BBB, astrocytes |
Km ~ 6 mM; high capacity |
| GLUT2 |
SLC2A2 |
Astrocytes, some neurons |
Km ~ 17 mM; low affinity |
| GLUT3 |
SLC2A3 |
Mature neurons |
Km ~ 1.6 mM; high affinity |
| GLUT4 |
SLC2A4 |
Some neurons |
Insulin-responsive |
| GLUT5 |
SLC2A5 |
Microglia |
Fructose-specific |
- SLC16A1 (MCT1): Ketone body transporter, complementary function
- SLC16A7 (MCT2): Neuronal ketone transporter
- SLC2A3 (GLUT3): High-affinity neuronal glucose transporter (backup)
- HIF1A: Transcription factor that upregulates SLC2A1
- PIK3R1 (PI3K): Insulin signaling pathway cross-talk
- Hexokinases (HK1, HK2, HK3): Phosphorylate glucose after import
- Glycogen synthase (GYS1): Astrocyte glycogen synthesis from imported glucose
- Lactate dehydrogenase (LDHA/B): Conversion of glucose to lactate
- PDH (PDHA1): Pyruvate dehydrogenase entry to mitochondria
- Heterozygous KO (GLUT1+/-): Reduced BBB GLUT1, glucose hypometabolism, mild phenotypes
- Homozygous KO: Lethal in embryogenesis (GLUT1 is essential for early development)
- Conditional KO: Brain-specific deletion shows behavioral and cognitive deficits
- SLC2A1 haploinsufficient mice: Recapitulate human GLUT1 deficiency syndrome
- Epilepsy phenotype: Spontaneous seizures in GLUT1+/- mice
- Movement disorder: Ataxia and dystonia features
- Response to ketogenic diet: Phenotypic improvement with ketone body supplementation
- 5xFAD mice: Show reduced GLUT1 at BBB with aging
- MPTP models: GLUT1 reduction in the substantia nigra
- SOD1-G93A mice: GLUT1 reduction in motor neurons precedes symptoms
- Aging models: GLUT1 decline with age, accelerates amyloid pathology